Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 7/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 8/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4641179 | 0.92 | SIRT6 (0.60) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL6978950 | 0.88 | SIRT6 (0.65) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL27997682 | 0.86 | SIRT6 (0.75) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL30532598 | 0.86 | SIRT6 (0.75) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL40059 | 0.84 | HPGD (0.68) | MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL22652197 | 0.84 | MAPT (0.51) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL22652221 | 0.84 | L3MBTL1 (0.51) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL11296150 | 0.84 | MAPT (0.50) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL170932 | 0.83 | HPGD (0.75) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL22652212 | 0.82 | MAPT (0.51) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983081-B1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260007668-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12377097-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250084073-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-03-13 | — | — | US | disclosed |
| CN-119241444-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119176782-A | Aminopyrimidinamide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-12-24 | — | — | CN | disclosed |
| CN-118930524-A | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118878520-A | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118878519-A | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-28 | — | — | US | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007048088-A2 | METHOD OF INHIBITING FLT3 KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006138155-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
| US-20060189623-A1 | Inhibitors of c-fms kinase | ILLIG CARL R | 2006-08-24 | — | — | US | disclosed |
| US-20060148812-A1 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189623-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | SIRT6 4653/4885MAPT 147/4885ALDH1A1 4789/4885 |
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | SIRT6 2160/4885MAPT 710/4885ALDH1A1 3129/4885 |
| US-20060281788-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR | FLT3, MCL1, CSF1R | SIRT6 1407/4885MAPT 4541/4885ALDH1A1 1900/4885 |
| US-12377097-B2 | Aminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | SIRT6 521/4885MAPT 940/4885ALDH1A1 2251/4885 |
| US-20060148812-A1 | Inhibitors of c-fms kinase | MUSK, TYK2, FES | SIRT6 4653/4885MAPT 147/4885ALDH1A1 4789/4885 |
| US-20260007668-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | SIRT6 388/4885MAPT 891/4885ALDH1A1 2888/4885 |
| US-20250084073-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | SIRT6 651/4885MAPT 817/4885ALDH1A1 2271/4885 |
| US-20070149572-A1 | METHOD OF INHIBITING FLT3 KINASE | FLT3, PLK1, PHKG1 | SIRT6 2170/4885MAPT 850/4885ALDH1A1 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.